Finance News

Ionis Pharmaceuticals to Hold 2017 Financial Results Conference Call

3.2 from 6 votes
Wednesday, February 14, 2018

CARLSBAD, Calif. - Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced that it will host a live webcast on Tuesday, February 27 at 11:30 a.m. Eastern Time to discuss its 2017 financial results and report on pipeline and business progress.

Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at A webcast replay will be available for a limited time at the same address.

Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development. SPINRAZA (nusinersen) has been approved in global markets for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. Drugs that have successfully completed Phase 3 studies include inotersen, an antisense drug Ionis is developing to treat patients with hereditary TTR amyloidosis (hATTR), and volanesorsen, an antisense drug discovered by Ionis and co-developed by Ionis and Akcea Therapeutics to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy. Akcea, an affiliate of Ionis, is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. If approved, volanesorsen will be commercialized through Ionis' affiliate, Akcea. Inotersen filings for marketing approval are under review in the U.S. and EU. Volanesorsen filings for marketing approval are under review in the U.S., EU, and Canada. Ionis' patents provide strong and extensive protection for its drugs and technology. Additional information about Ionis is available at

Communications and Investor Relations
Ionis Pharmaceuticals
Phone: 760-603-274

Source: Ionis Pharmaceuticals, Inc.
3.2 from 6 votes
Free Newsletter